The Short-Acting Insulin Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The global short-acting insulin market has seen substantial growth recently. The market size is projected to increase from $11.00 billion in 2024 to $11.65 billion in 2025, signifying a compound annual growth rate (CAGR) of 5.9%.
The Short-Acting Insulin Global Market Report 2025 predicts that by 2029, the market will expand to a size of $14.47 billion, with a compound annual growth rate (CAGR) of 5.6%.
Download Your Free Sample of the 2025 Short-Acting Insulin Market Report and Uncover Key Trends Now!The key drivers in the short-acting insulin market are:
• Uptick in governmental initiatives and support for insulin therapy
• Rapid innovations in the production of short-acting insulin
• Increasing global adoption of insulin therapy and personalized medicine
• Advancements in insulin delivery devices and technologies, including development of biosimilars and innovative fast-acting insulin analogs.
The short-acting insulin market covered in this report is segmented –
1) By Formulation: Regular Insulin, Rapid-Acting Insulin
2) By Dosage Form: Vials, Pre-filled Pens, Cartridges
3) By Route Of Administration: Subcutaneous, Intravenous
4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes
5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies
Subsegments:
1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin
2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine
The key trends in the short-acting insulin market are:
• Advancements in insulin delivery devices and technologies are emerging trends in the market.
• Innovative fast-acting insulin analogs are shaping the future of the market.
• The development of biosimilars is a significant trend in the market.
• There's a shift towards patient-centric care, driving changes in the market.
Major players in the short-acting insulin market are:
• Sanofi S.A.
• Eli Lilly and Company
• Novo Nordisk A/S
• Baxter International Inc.
• Eisai Co. Ltd.
• Sumitomo Pharma Co. Ltd.
• Biocon Limited
• Kissei Pharmaceutical Co. Ltd.
• Lupin Limited
• Wockhardt Ltd.
• Lannett Co. Inc.
• MannKind Corporation
• Sihuan Pharmaceutical Holdings Group Ltd.
• Julphar(Gulf Pharmaceutical Industries)
• Geropharm LLC
• Bioton S.A.
• hec pharm co. ltd
• ADOCIA SAS
• Gan & Lee Pharmaceuticals Co. Ltd.
• Adocia S.A.S.
North America was the largest region in the short-acting insulin market in 2024